Phase 2 trial of GO-203 in combination with decitabine for patients with AML who (i) are not candidates for induction chemotherapy, or (ii) have relapsed/refractory disease
(current)

• full details

Phase 1b trial of GO-203 in combination with decitabine for patients with relapsed/refractory AML
(completed)

• established acceptable safety profile (toxicity and efficacy)

Phase 1b trial of GO-203 for patients with relapsed/refractory AML
(completed)

• established acceptable safety profile (toxicity and efficacy)

GO-203
(completed)

• for patients with advanced solid tumors or lymphomas
• established acceptable safety profile (toxicity and efficacy)
• full details and results